Lakshmi Rekha Narra

Dr. Lakshmi Rekha Narra


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2025 in Seminars in Pediatric Neurology
Verified
Journal Article
Open access
RKRitesh Kumar
Ritesh Kumar
LNLakshmi Rekha Narra
Lakshmi Rekha Narra
ZSZohaib Sherwani
Zohaib Sherwani
RPRahul R Parikh
Rahul R Parikh
Radiation therapy plays a pivotal role in treating pediatric central nervous system (CNS) tumors. However, its potential long-term impact on neurological function poses significant challenges. In this review, we examine the scope of neurological sequelae in survivors of pediatric CNS tumors, with a focus on clinical manifestations, evaluation methods, and management strategies. Key areas discussed include neurocognitive deficits, endocrine dysfunctions, cerebrovascular complications, and secondary malignancies. Emphasis is placed on mitigating radiation-induced toxicity through advanced radiotherapy techniques and integrated survivorship care.

19 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
LNLakshmi Rekha Narra
Lakshmi Rekha Narra
RKRitesh Kumar
Ritesh Kumar
MDMatthew P. Deek
Matthew P. Deek
SJSalma Jabbour
Salma Jabbour
Unresectable stage III non-small-cell lung cancer (NSCLC) remains a clinical challenge, due to the need for optimal local and systemic control. The management of unresectable Stage III NSCLC has evolved with advancements in radiation therapy (RT), systemic therapies, and immunotherapy. For patients with locally advanced NSCLC who are not surgical candidates, concurrent chemoradiotherapy (CRT) has modest survival outcomes, due to both local progression and distant metastasis. Efforts to enhance outcomes have led to dose-escalation trials, advances in modern RT techniques such as intensity-modulated RT (IMRT) and proton beam therapy (PBT), and the integration of adaptive RT to optimize target coverage while sparing organs at risk. Concurrent and consolidative immunotherapy, particularly with PD-L1 inhibitors, has shown promise, as evidenced by the PACIFIC trial, which demonstrated improved progression-free survival (PFS) and overall survival (OS) with durvalumab following CRT. Ongoing trials are now investigating novel immunotherapy combinations and targeted therapies in this setting, including dual checkpoint inhibition, DNA repair inhibitors, and molecularly targeted agents like osimertinib for EGFR-mutated NSCLC. Emerging biomarkers, such as circulating tumor DNA and radiomics, offer potential for personalizing treatment and predicting outcomes. Additionally, PBT and MR-guided adaptive RT have shown the potential to reduce toxicities while maintaining efficacy. Integrating these novel approaches may offer opportunities for optimizing treatment responses and minimizing adverse effects in this challenging patient population. Further investigation into patient stratification, biomarker-driven therapy, and refined therapeutic combinations is essential to improve long-term outcomes in unresectable Stage III NSCLC. This narrative review explores the current management strategies for unresectable Stage III NSCLC, from a radiation oncology perspective.

Verified
Journal Article
Open access
PDF file
SMSwati Mamidanna
Swati Mamidanna
MBMenal Bhandari
Menal Bhandari
CSCharvi Shah
Charvi Shah
LBLudvinna Bazile
Ludvinna Bazile
SGSukhdeep Gill
Sukhdeep Gill
RKRitesh Kumar
Ritesh Kumar
Small cell lung cancer (SCLC) is an aggressive malignancy with a high incidence of brain metastases. Prophylactic cranial irradiation (PCI) was developed to reduce central nervous system (CNS) relapses and has been shown to improve survival, particularly in limited-stage disease. The pivotal Auperin meta-analysis and subsequent studies confirmed its role in patients achieving a complete response to initial therapy. In extensive-stage SCLC, earlier trials demonstrated reduced brain metastases and modest survival gains, but more recent studies incorporating routine magnetic resonance imaging (MRI) surveillance failed to show overall survival benefits, supporting MRI monitoring with salvage therapy as an alternative. Neurocognitive toxicity remains the major limitation of PCI, especially in older adults. Common effects include memory impairment, cognitive changes, and a reduced quality of life. Advances such as hippocampal avoidance PCI and neuroprotective strategies like memantine have shown the ability to mitigate long-term decline. Modern radiotherapy techniques, including intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT), enable the precise sparing of critical structures while maintaining intracranial control. The integration of immunotherapy has shifted treatment paradigms in SCLC. While checkpoint inhibitors have improved systemic outcomes, their impact on brain relapses and interactions with PCI remain uncertain. This review provides an overview of the evolution of PCI in SCLC, while emphasizing current challenges and future directions.